Degradation of estrogen receptor α in activated blastocysts is associated with implantation in the delayed implantation mouse model
2014
Implantation of a blastocyst into a receptive uterus involves a series of highly coordinated cellular and molecular events directed by ovarian estrogen and progesterone. In particular, estrogen is essential for on-time uterine receptivity and blastocyst activation in mice. Although estrogen receptora (ERa) is expressed in blastocysts, its targeted disruption leaves embryonic development and implantation unaffected. There- fore, the role of ERa in implanting blastocysts remains unclear. Using a delayed implantation model in mice, we showed increased expression of ERa in implantation-induced (activated) blastocysts; however, this ERa expression in activated blastocysts decreased within 6-h culture. In con- trast, breast cancer 1 (Brca1) was maintained in the blastocysts during the culture. The treatment of activated blastocysts with the proteasome inhibitor MG132 demonstrated that proteolysis is associated with down-regulation of ERa expression in activated blastocysts. Embryo transfer of MG132-treated activated blastocysts into recipient mice on the morning of Day 4 of pseudopregnancy (Day 1 ¼ vaginal plug) showed a decreased implantation rate, whereas combined treatment with MG132 and the ER antagonist, ICI 182,780, resulted in recovery of the rate of implantation. This study has revealed that down-regulation of ERa in activated blastocyst is associated with completion of blastocyst implantation after embryo transfer on the morning of Day 4 of pseudopregnancy. Our results also suggest that selective protein turnover, such as that of ERa, occurs in activated blastocysts, while expression of other proteins, including Brca1, is maintained at the same stage.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
9
Citations
NaN
KQI